Focusing on testosterone.


Journal Article

Since Huggins and Hodges first established testosterone as the principal androgenic hormone responsible for the growth of prostate cancer in 1941, lowering the circulating testosterone to surgical castration levels (<50 ng/dL) has been a fundamental strategy for prostate cancer therapy. Until the 1980s, surgical castration (bilateral orchiectomy) and medical castration using estrogen (diethylstilbestrol) were the primary methods of testosterone suppression. However, during the past 30 years, newer agents that lower serum testosterone even more effectively have been approved and the indications for use of these newer agents re-evaluated.

Full Text

Duke Authors

Cited Authors

  • Moul, JW; Dreicer, R

Published Date

  • November 2011

Published In

Volume / Issue

  • 78 / 5 Suppl

Start / End Page

  • S476 - S477

PubMed ID

  • 22054917

Pubmed Central ID

  • 22054917

Electronic International Standard Serial Number (EISSN)

  • 1527-9995

Digital Object Identifier (DOI)

  • 10.1016/j.urology.2011.06.004


  • eng

Conference Location

  • United States